Brief Communication: Delayed Graft Function and Acute Rejection Following HLA-Incompatible Living Donor Kidney Transplantation

• Published in: American journal of transplantation Vol. 21; no. 4; pp. 1612 - 1621
• Main Authors: Motter, Jennifer D., Jackson, Kyle R., Long, Jane J., Waldram, Madeleine M., Orandi, Babak J., Montgomery, Robert A., Stegall, Mark D., Jordan, Stanley C., Benedetti, Enrico, Dunn, Ty B., Ratner, Lloyd E., Kapur, Sandip, Pelletier, Ronald P., Roberts, John P., Melcher, Marc L., Singh, Pooja, Sudan, Debra L., Posner, Marc P., El-Amm, Jose M., Shapiro, Ron, Cooper, Matthew, Verbesey, Jennifer E., Lipkowitz, George S., Rees, Michael A., Marsh, Christopher L., Sankari, Bashir R., Gerber, David A., Wellen, Jason R., Bozorgzadeh, Adel, Gaber, A. Osama, Heher, Eliot C., Weng, Francis L., Djamali, Arjang, Helderman, J. Harold, Concepcion, Beatrice P., Brayman, Kenneth L., Oberholzer, Jose, Kozlowski, Tomasz, Covarrubias, Karina, Massie, Allan B., Segev, Dorry L., Garonzik-Wang, Jacqueline M.
• Format: Journal Article
• Language: English
• Published: 27-02-2021
• ISSN: 1600-6135; 1600-6143
• DOI: 10.1111/ajt.16471

Incompatible living donor kidney transplant recipients (ILDKTr) have pre-existing donor-specific antibody (DSA) that, despite desensitization, may persist or reappear with resulting consequences, including delayed graft function (DGF) and acute rejection (AR). To quantify the risk of DGF and AR in ILDKT and downstream effects, we compared 1,406 ILDKT to 17,542 compatible LDKT recipients (CLDKTr) using a 25-center cohort with novel SRTR linkage. We characterized DSA strength as positive-Luminex, negative-flow crossmatch (PLNF); positive-flow, negative-cytotoxic crossmatch (PFNC); or positive-cytotoxic crossmatch (PCC). DGF occurred in 3.1% of CLDKT, 3.5% of PLNF, 5.7% of PFNC, and 7.6% of PCC recipients, which translated to higher DGF for PCC recipients (aOR=
1.03
1.68
2
.72
). However, the impact of DGF on mortality and DCGF risk was no higher for ILDKT than CLDKT (p interaction>0.1). AR developed in 8.4% of CLDKT, 18.2% of PLNF, 21.3% of PFNC, and 21.7% of PCC recipients, which translated to higher AR (aOR PLNF=
1.45
2.09
3.02
;PFNC=
1.67
2.40
3.46
;PCC=
1.48
2.24
3.37
). Although the impact of AR on mortality was no higher for ILDKT than CLDKT (p interaction=0.1), its impact on DCGF risk was less consequential for ILDKT (aHR=
1.34
1.62
1.95
) than CLDKT (aHR=
1.96
2.29
2.67
) (p interaction=0.004). Providers should consider these risks during pre-operative counselling, and strategies to mitigate them should be considered.